The Autism Impact Fund, whose mission is to revolutionize the status quo for diagnosing, treating and living with autism, has made its first venture capital investments in seven growth and early-stage companies:
Axial, which is a clinical-stage biopharmaceutical company focused on developing a pipeline of gut-restricted small molecule agents intended for the treatment of autism, other CNS disorders, and cancer;
BioROSA, which is developing an objective blood test for diagnosing autism;
Floreo, which provides a range of behavioral therapies through a telehealth-enabled virtual reality platform;
Joshin, which is a digital platform that connects employers and families with special needs to qualified caregivers through an experience tailored to their goals;
SpectrumAi, which is modernizing and democratizing access to high-quality autism treatment
Suggestic, which is an AI-driven platform for developers that integrates personal health data, provider recommendations, and tailored nutrition support to deliver actionable health journeys for end-users
Yamo Pharmaceuticals, which is a drug discovery company developing a therapeutic for core autism symptoms. Read more.
